B. Metzler seel. Sohn & Co. AG Has $4.71 Million Position in Edwards Lifesciences Co. (NYSE:EW)

B. Metzler seel. Sohn & Co. AG trimmed its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 20.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 63,646 shares of the medical research company’s stock after selling 16,712 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in Edwards Lifesciences were worth $4,712,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in EW. Summit Financial LLC lifted its stake in shares of Edwards Lifesciences by 5.0% in the 4th quarter. Summit Financial LLC now owns 6,076 shares of the medical research company’s stock valued at $450,000 after acquiring an additional 288 shares during the last quarter. AIA Group Ltd increased its holdings in Edwards Lifesciences by 24.2% in the 4th quarter. AIA Group Ltd now owns 930,933 shares of the medical research company’s stock worth $68,917,000 after purchasing an additional 181,409 shares in the last quarter. Wellington Management Group LLP raised its position in Edwards Lifesciences by 5.3% in the fourth quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company’s stock valued at $2,458,601,000 after purchasing an additional 1,678,154 shares during the last quarter. Partners in Financial Planning acquired a new stake in shares of Edwards Lifesciences during the fourth quarter valued at about $858,000. Finally, Schroder Investment Management Group bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $7,176,000. Institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Evercore ISI cut their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research report on Wednesday, February 12th. Citigroup boosted their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Wolfe Research lowered Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Piper Sandler increased their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Finally, Barclays raised their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Stock Up 2.3 %

Shares of NYSE:EW opened at $72.56 on Tuesday. The firm has a market cap of $42.66 billion, a P/E ratio of 10.41, a PEG ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $95.73. The business’s 50 day simple moving average is $71.55 and its two-hundred day simple moving average is $70.56. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, research analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total transaction of $797,287.50. Following the completion of the sale, the chief financial officer now directly owns 30,387 shares of the company’s stock, valued at approximately $2,153,526.69. The trade was a 27.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. This represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 62,553 shares of company stock valued at $4,513,064 over the last three months. Corporate insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.